Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Table 5 Cox regression model of multivariable analysis for overall survival and progression-free survival

	HR (95% CI)	P value
Overall survival
Cetuximab (yes vs. no)	1.457 (0.639 ~ 3.322)	0.371
Smoking history (yes vs. no)	1.217 (0.537 ~ 2.757)	0.638
Disease stage (IV vs. II–III)	5.052 (2.194 ~ 11.631)	< 0.001
EBVDNA (≥ vs. < 4000 copies)	2.072 (0.878 ~ 4.893)	0.096
BMI (≥vs. < 23 kg/m²)	0.84 (0.373 ~ 1.893)	0.674
CRP (≤ vs. >3.0 g/ml)	0.736 (0.267 ~ 2.027)	0.553
VCA-IgA (< vs. ≥ 1:80)	0.877 (0.209 ~ 3.687)	0.858
EA-IgA (< vs. ≥ 1:10)	0.894 (0.24 ~ 3.326)	0.867
Family history of cancer (yes vs. no)	0.953 (0.271 ~ 3.346)	0.94
Progression-free survival
Cetuximab (yes vs. no)	1.85 (0.956 ~ 3.58)	0.068
Smoking history (yes vs. no)	0.917 (0.47 ~ 1.79)	0.8
Disease stage (IV vs. II–III)	3.747 (1.823 ~ 7.704)	< 0.001
EBVDNA (≥ vs. < 4000 copies)	1.127 (0.571 ~ 2.222)	0.731
BMI (≥vs. < 23 kg/m²)	0.802 (0.424 ~ 1.517)	0.497
CRP (≤ vs. >3.0 g/ml)	1.315 (0.644 ~ 2.688)	0.452
VCA-IgA (< vs. ≥ 1:80)	1.087 (0.376 ~ 3.143)	0.877
EA-IgA (< vs. ≥ 1:10)	0.712 (0.268 ~ 1.892)	0.496
Family history of cancer (yes vs. no)	0.678 (0.233 ~ 1.97)	0.302

Abbreviations: EA early antigen, VCA viral capsid antigen, IgA immunoglobulin A, EBV DNA Epstein-Barr virus DNA, CRP C-reactive protein, BMI Body Mass Index

ISSN: 1471-2407